In 2008, US health care spending growth dropped to 4.4%, the slowest rate of growth over the past 40 years, according to data from a study published yesterday in the journal Health Affairs based on an analysis by the nation's federal agency, the Centers for Disease Control and Prevention (CMS), part of the US Department of Health and Human Services.
The deceleration was broadly based for nearly all payers and health care goods and services, as growth in both price and non-price factors slowed amid the recession. Despite the slowdown, national health spending reached $2,300 billion, or $7,681 per person, and the health care portion of Gross Domestic Product grew from 15.9% in 2007 to 16.2% in 2008. These developments reflect the general pattern that larger increases in the health spending share of GDP generally occur during or just after periods of economic recession. Despite the overall slowdown in national health spending growth, increases in this spending continue to outpace growth in the resources available to pay for it.
Retail prescription drugs
According to the study, in 2008, retail prescription drug spending growth decelerated to 3.2%, reflecting the continuation of a slowing trend that began in 2000. Additionally, prescription drug spending growth attributable to non-price factors (such as use and intensity) slowed in 2008, as per capita use of prescription drugs declined slightly. Impacts of the recession, a low number of new product introductions, and safety concerns all contributed to lower use per person.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze